Locations:
Search IconSearch
August 14, 2024/Innovations

Crain’s Cleveland Business: Centerline Biomedical Looks to Change ‘Current Gold Standard’ for Endovascular Intervention

Cleveland Clinic Innovations portfolio company Centerline Biomedical’s Intra-Operative Positioning System (IOPS) aims to help clinicians visualize endovascular tools in real-time and reduce their dependence on fluoroscopy systems.

Doctor with endovascular model

The use of fluoroscopy in orthopedic procedures presents a potential health risk to surgeons due to radiation exposure, even with the use of protective equipment. Centerline Biomedical, a Cleveland Clinic Innovations med-tech portfolio company, aims to address this issue with its Intra-Operative Positioning System (IOPS). Recently receiving FDA clearance for its IOPS Viewpoint Catheter, the company's technology aims to reduce reliance on fluoroscopy systems and protect clinicians from radiation exposure.

The IOPS system, based on electromagnetic tracking, creates real-time visualization of endovascular tools, offering a safer alternative to fluoroscopy. Developed as a collaboration between former Cleveland Clinic researcher Vikash Goel and the late Dr. Roy Greenberg, the technology aims to improve visualization during endovascular interventions and reduce the health risks associated with prolonged radiation exposure for surgeons.

Centerline Biomedical's IOPS system, designed to provide real-time navigation feedback, consists of a portable cart, electromagnetic field generator, sensor interface unit, and specially designed catheters and guidewires with integrated sensors. The company has been continually improving its system based on feedback from early adopters and is set to release new hardware and software updates, with plans for further upgrades in the coming years. In addition to reducing radiation exposure, the IOPS technology has the potential to enhance efficiency in the operating room, allowing doctors to work more effectively by providing clearer visualization. With the appointment of a new Chief Financial Officer and a successful $33 million Series B equity financing round in 2022, Centerline Biomedical is poised to further advance its mission of providing a safer and more efficient alternative to fluoroscopy for orthopedic procedures.

Read the full article via Crain’s Cleveland Business.

Subscribe to Cleveland Clinic Innovations' Newsletter

Follow Cleveland Clinic Innovations on LinkedIn

Latest from the Newsroom

Beri Ridgeway, M.D.

Cleveland Clinic Appoints Beri Ridgeway, M.D., as President of Cleveland Clinic London

Genediting Therapy Shows Success Against Severe Sickle Cell Disease

Gene Editing Therapy Shows Success Against Severe Sickle Cell Disease

Cleveland Clinic's Main Campus lobby

Mandel Foundation Donates $50 Million to Improve Access to Care at Cleveland Clinic

Blood pressure cuff

Experimental Monthly Injectable Reduces a Key Regulator of Blood Pressure

GLP-1 injection pen with a stethoscope

Tirzepatide Associated with Lower Risk of Heart and Kidney Damage Compared to Dulaglutide in Patients with Type 2 Diabetes and Cardiovascular Disease

Hospital Care At Home

Cleveland Clinic Introduces Hospital Care At Home in Ohio

Image of a scaled and tape measure

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights

Illustration of digital medical records

AI-Driven Chart Review Accurately Identifies Potential Rare Disease Trial Participants in New Study